Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14313MR)

This product GTTS-WQ14313MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Solid tumors, Colorectal Cancer (CRC) Cancers (CRC) Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14313MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8952MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ2372MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ3387MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ4898MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ1488MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ7415MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ12545MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ5738MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW